InsidersTradesSigma
Browse the complete record of transactions filed by Flynn Karen, Président des Biologiques et CCO. Director active across 2 companies, notably Catalent, Inc.. Cumulatively, 5 reports have been published. Total volume traded: €508k. The latest transaction was disclosed on 6 June 2022 — Attribution. Regulator: SEC (Form 4). The full history is openly available.
5 of 5 declarations
Karen Flynn is the President of Biologics and CCO at Catalent, Inc. and Quanterix Corp. She oversees the company's commercial and strategic operations. Her role is crucial in ensuring growth and innovation in the biopharmaceutical sector.